Related Experiment Video

Updated: Aug 8, 2026

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

Complement and complement regulatory proteins as potential molecular targets for vascular diseases

Juan Acosta1, Xuebin Qin, Jose Halperin

  • 1Hematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, USA.

Current Pharmaceutical Design
|February 3, 2004
PubMed

Insights

Complement activation by-products and regulatory proteins contribute to vascular diseases like atherosclerosis and diabetes. Targeting these complement components offers a promising strategy for developing new mechanism-specific therapies.

Area of Science:

  • Immunology
  • Vascular Biology
  • Pathophysiology

Background:

  • Complement activation by-products and regulatory proteins are implicated in vascular pathologies.
  • Autologous complement-mediated damage occurs via cascade products or membrane attack complex (MAC) insertion.
  • MAC insertion into endothelial cells triggers growth factor/cytokine release, promoting vascular proliferation, inflammation, and thrombosis.

Purpose of the Study:

  • To review the role of complement and its regulators in vascular diseases.
  • To highlight complement as a therapeutic target for prevalent human diseases.

Main Methods:

  • Literature review focusing on complement pathways and vascular disease mechanisms.
  • Analysis of the pathogenic role of complement activation products and regulatory proteins.

Main Results:

  • Complement system components are key players in atherosclerosis, ischemia-reperfusion injury, graft rejection, vasculitis, and diabetic vascular complications.
  • Endothelial cell activation by MAC leads to pro-inflammatory and pro-thrombotic responses.

Conclusions:

  • The complement system and its regulators are critical in vascular disease pathogenesis.
  • Targeting complement pathways presents a rational approach for developing novel therapeutic strategies for vascular diseases.

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Antimicrobial Proteins01:23

Antimicrobial Proteins

Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...